ASENSUS SURGICAL, INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019
Current Assets:
Cash and cash equivalents
Short-term investments
Short-term investments, available-for-sale
Accounts receivable, net
Inventories
Interest receivable
Prepaid expenses
Employee retention tax credit receivable
Other current assets
Total Current Assets
Restricted cash
Long-term investments, available-for-sale
Inventories, net of current portion
Property and equipment, net
Intellectual property, net
Intellectual Property
In Process Research and Development
Total intellectual property, net

Goodwill
Net deferred tax assets
Operating lease right-of-use assets, net
Other long-term assets
Total Assets

Current Liabilities:
Accounts payable
Accrued employee compensation and benefits
Accrued expenses and other current liabilities
Contingent consideration, current
Deferred consideration - MST Acquisition
Operating lease liabilities, current
Deferred revenue
Notes payable - current portion, net of debt discount
Notes payable
Total Current Liabilities

Long-Term Liabilities:
Deferred revenue - less current portion
Contingent consideration
Notes payable, net of debt discount
Notes payable, net of issuance costs
Warrant liabilities
Noncurrent operating lease liabilities
Notes payable, less current portion
Net deferred tax liabilities
Other long term liabilities
Total Liabilities

Stockholders' Equity:
Common stock $0.001 par value, 750,000,000 shares authorized at June 30, 2024 and December 31, 2023; 272,616,330 and 264,921,526 issued and outstanding at June 30, 2024 and December 31, 2023, respectively
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total Stockholders' Equity
Total Liabilities and Stockholders' Equity

Comments